Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pasithea TherapeuticsKTTA -3.89%29 Buyback Yield % is -379.87 as of Jul. 21, 2026. GuruFocus rates KTTA with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 740 Biotechnology companies, Pasithea Therapeutics ranks worse than 97.3% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Pasithea Therapeutics Buyback Yield % Related Terms
Pasithea Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Pasithea Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KTTA vs CELU, GRTX, BCDA: Buyback Yield % Comparison
For the Biotechnology subindustry, Pasithea Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pasithea Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Pasithea Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pasithea Therapeutics (KTTA) has a Buyback Yield % of -379.87 as of Jul. 21, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Pasithea Therapeutics and its competitors. According to the industry distribution chart, Pasithea Therapeutics ranks #720 out of 740 companies in the Biotechnology industry, placing it in the top 97.3%.
Is Pasithea Therapeutics' Buyback Yield % too high?
Pasithea Therapeutics' current Buyback Yield % is -379.87. Based on the distribution chart, Pasithea Therapeutics ranks #720 out of 740 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pasithea Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Pasithea Therapeutics' Buyback Yield % compare to CELU and GRTX?
According to the Biotechnology industry distribution chart, Pasithea Therapeutics ranks #720 out of 740 companies for Buyback Yield %. This places Pasithea Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Pasithea Therapeutics and its competitors. Pasithea Therapeutics's current Buyback Yield % is -379.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pasithea Therapeutics stock overvalued right now?
Pasithea Therapeutics (KTTA) has a current Buyback Yield % of -379.87. The current Buyback Yield % is -379.87. Pasithea Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Pasithea Therapeutics (KTTA), the current Buyback Yield % is -379.87 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
29GF Score
Get the complete analysis for KTTA
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KTTA has been successfully added to your 
